P/E ratio for Fortress Biotech (FBIO)
P/E ratio as of May 2024 (TTM): -0.1668
According to Fortress Biotech 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.166821. At the end of 2022 the company had a P/E ratio of -0.0620.
P/E ratio history for Fortress Biotech from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0620 | -83.8% |
| 2021 | -0.3828 | 5.8% |
| 2020 | -0.3619 | -5.38% |
| 2019 | -0.3824 | 832.98% |
| 2018 | -0.0410 | -78.2% |
| 2017 | -0.1880 | 1.26% |
| 2016 | -0.1857 | -5.09% |
| 2015 | -0.1957 | -31.44% |
| 2014 | -0.2854 | 60.81% |
| 2013 | -0.1775 | -23.86% |
| 2012 | -0.2331 | 268.66% |
| 2011 | -0.0632 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Veracyte VCYT | -50.5 | 30,156.98% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Advaxis ADXS | -0.0889 | -46.73% | 🇺🇸 USA |
 Dynavax Technologies
DVAX | 13.5 | -8,175.30% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.